Product
Supplier
Encyclopedia
Inquiry
Sodium 4-Phenylbutyrate buy - large image1
Sodium 4-Phenylbutyrate buy - image1

Sodium 4-Phenylbutyrate

4 Inquiries

Unit Price: Get Latest Price
CAS No.:

1716-12-7

Grade:

Pharmaceutical Grade

Port:

QINZHOU

Packaging:

25kg/2.5kg Fiber Drum

Price valid (until):

2017-06-19

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

4-hydroxyl-7-methoxyquinoline, quinoline, quinolin, pyrazine, indole, midiazol, borane, silicane, and, raw materials

  • Product Description

  • Seller Information

  • Inquiry History

  • Description

    Sodium phenylbutyric acid is metabolized in the body by beta-oxidized phenyl acetate, and the phenyl acetate is then conjugated with glutamyl aminoacylol, and the two reactions are relatively rapid and complete. Benzene acetyl glutamine ammonia as an alternative waste nitrogen urea product, renal excretion through, compared with urea at Moore level, both per mole all contains 2 Moore nitrogen (i.e., 1 mole phenyl butyric acid sodium can also remove 2 Moore source of amino acid nitrogen). According to the report, the use of sodium phenylbutyric acid in the treatment of urea circulatory disorders (the combined control of dietary nitrogen intake), the blood ammonia and haematine levels can be reduced or even normal.

    The pharmacological action of sodium benzoate

    Sodium phenylbutyric acid is metabolized in the body by beta-oxidized phenyl acetate, and the phenyl acetate is then conjugated with glutamyl aminoacylol, and the two reactions are relatively rapid and complete. Benzene acetyl glutamine ammonia as an alternative waste nitrogen urea product, renal excretion through, compared with urea at Moore level, both per mole all contains 2 Moore nitrogen (i.e., 1 mole phenyl butyric acid sodium can also remove 2 Moore source of amino acid nitrogen). According to the report, the use of sodium phenylbutyric acid in the treatment of urea circulatory disorders (the combined control of dietary nitrogen intake), the blood ammonia and haematine levels can be reduced or even normal.

    Sodium phenylbutyric acid

    Treatment for urea cycle disorders.

    Sodium phenylbutyric acid

    Allergic to phenylbutyric acid or phenyl acetate.

    The emergency treatment is banned for acute hyperamemia.

    Severe hypertension, heart failure, kidney failure.

    Matters needing attention

    (1) low, moderate hypertension, heart failure, insufficiency of kidney function, or other edema associated with sodium retention. (2) the liver is not fully functional. (3) obese patients.

    The effects of drugs on children: it is reported that children taking phenylbutyric acid can produce unpredictable adverse reactions; Child medication, its own severe symptoms and brain damage may continue to worsen.

    The effect of the drug on pregnancy: there is no evidence of pregnant women in the country, and the U.S. drug and food administration (FDA) classifications for the safety of sodium benzoate in grade C.

    The effect of drugs on breastfeeding: the study of drug use by women is not sufficient and should be taken into consideration.

    (1) routine monitoring of serum protein and plasma levels of ammonia, glutamate, and arginine should be monitored. (2) if necessary, the liver and kidney work should be monitored, serum albumin, total protein, arterial blood gas analysis, blood electrolyte concentration, white blood cell classification and counting, platelet count and urine analysis.

    Storage: avoid light and keep at room temperature.

    Sodium phenylbutyric acid

    Cardiovascular system: ankle and peripheral edema, abnormal blood pressure changes, rare arrhythmias and fainting.

    Nervous system: headaches and depression.

    3. Metabolic/endocrine system: can cause low serum albumin leels (about 10%), metabolic acidosis (14%), (7%), high blood chlorine alkali poisoning (7%), also can cause high uric acid blood disease, hypokalemia, low phosphorus, hyperphosphatemia, high sodium (incidence of less than 6%).

    Urogenital system: often causes irregular periods of menstruation of women, and even menopause (about 23%). Rare phenylbutyric acid is the cause of renal tubular acidosis.

    Liver: can cause the serum aminotransferase, bilirubin, alkaline phosphatase level to rise, there is no report on the toxicity of phenylbutyric acid.

    6. The gastrointestinal tract: common lack of appetite (about 4%), also can cause poor taste, abdominal pain, nausea, vomiting, gastritis, unusual sodium phenyl butyric acid peptic ulcer, rectal bleeding, constipation, pancreatitis.

    Blood: may cause anemia (including aplastic anemia), leukocyte decrease or increase, platelets decrease, rare phenylbutyric acid can cause platelets to increase.

    Skin: even rash.

    Other: after sodium benzoate is taken, it may cause a bad smell.

    Sodium phenylbutyric acid

    Oral medicine: usually 4 to 6 times a day, the daily dosage of medicine is less than 20g. The safety and effectiveness of more than 20 grams of drugs per day has not been determined. Children's normal dosage: oral medicine: body weight is less than 20kg children, 450 ~ 600mg/kg a day, 4 ~ 6 times to the medicine, taking the medicine at mealtime, the total amount of medicine is less than 20g per day. It is recommended to use sodium phenylbutyric acid, not recommended for sodium benzoate. Weigh more than 20 kg and use the same amount as adults. Dosage of foreign usage: oral medicine: 9.9 ~ 13g/m2, the safety and effectiveness of more than 20g a day are not determined. Experiments show that liver function is full-time dose: have not been urea cycle disorder of hepatic insufficiency, phenyl butyric acid metabolism and excretion of sodium is not affected, there is no need to adjust the dose of data suggest that hepatic insufficiency, but needs further research. Children's regular doses: oral medicine: less than 20kg of children, 450 to 600 mg/kg a day; Weight is greater than 20k, use the same as adults.

    Drug interaction

    The combination of haloperidol, valproate, corticosteroid, and corticosteroids, may lead to high amenemia and should be used with caution.

    The renal excretion of the metabolite of ben-butyric acid is affected by the use of acetsu-sulfonate, which should be used with caution.


    Basic Info
    Product Name:

    Sodium phenylbutyrate

    Other Name:

    Benzenebutanoic acid,sodium salt (1:1);Butyric acid,4-phenyl-,sodium salt;Benzenebutanoic acid,sodium salt;Sodium phenylbutyrate;Sodium 4-phenylbutyrate;Sodium γ-phenylbutyrate;TriButyrate;Buphenyl;NSC 657802;Pheburane;Ammonaps

    CAS No.:

    1716-12-7

    Molecular Formula:

    C10H12O2.Na

    InChIKeys:

    InChIKey=SMWRDNDNSFPORN-UHFFFAOYSA-N

    Molecular Weight:

    186.18300

    Exact Mass:

    186.06600

    EC Number:

    605-612-7

    UNII:

    NT6K61736T

    DSSTox ID:

    DTXSID7040948

    NCI Thesaurus Code:

    C1440

    ATC Code:

    A16AX03|A - Alimentary tract and metabolism

    HScode:

    2916399090

    Categories:

    Inhibitors

    Characteristics
    PSA:

    40.13000

    XLogP3:

    0.75920

    Density:

    1.095g/cm3

    Melting Point:

    207 °C (dec.)(lit.)

    Boiling Point:

    290.7ºC at 760mmHg

    Flash Point:

    187.9ºC

    Storage Conditions:

    Desiccate at -20ºC

    Vapor Pressure:

    0.00288mmHg at 25°C

    Hazard Identification

    Classification of the substance or mixture

    Eye irritation, Category 2

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Warning

    Hazard statement(s)

    H319 Causes serious eye irritation

    Precautionary statement(s)
    Prevention

    P264 Wash ... thoroughly after handling.

    P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...

    Response

    P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

    Storage

    none

    Disposal

    none

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    4-hydroxyl-7-methoxyquinoline, quinoline, quinolin,pyrazine, indole, midiazol, borane, silicane, and,raw materials

    Location:

    Anhui province Chuzhou city Shahe Industrial Park District on Ying Road No. 2

    Payment Terms:

    TT against copy of documents

    Total Annual Revenue:

    $25 million-$50 million

    Total Employees:

    301-500

    Bai'ao Biology Technology Co., Ltd., mainly engages in the R&D, development, production and sales of pharmaceutical intermediates, compound essence, fine chemicals and biology chemistry. At the same time, it can provide technical advice, technical training, production arts improving and technical transforming and other service. The company owns 20,000 square meters modern production workshops in Chuzhou, Anhui Province which were equipped with completed production and testing equipments. It strictly carries out ISO9001-2000 Quality Guarantee System. The production arts and quality can all reach to international first class standard. There is R&D center in Dingjia Bridge, Gulou District, Nanjing. The R&D ability is strong with in depended research center as well as technical team made up of Doctors, Masters with rich experience. The enterprise has built all functional and all levels development and research in pharmacy, chemical and biotechnology with Nanjing University, China Pharmaceutical Universityy, Southeast University and Nanjing university of technology to provide timely, fast and efficient service.

    The enterprise adheres to seek survival from quality, development from technology, lead with market and service as philosophy as the management principle; environment protective, society repaying, employees caring as the social responsibility; moral, honest, innovation and practical as the pursuit and goal.


  • Inquiry History
    4 Inquiries
    Country Product Purchase Quantity Date Posted
    China

    sodium phenylbutyrate

    2 KG Oct 17, 2025
    Pakistan

    Sodium phenylbutyrate

    25 KG Sep 11, 2024
    Indonesia

    sodium phenylbutyrate

    250 G Sep 20, 2023
    Germany

    Sodium 4-phenylbutyrate

    1 KG May 26, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.